WP
ARQT icon

WealthPLAN Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

WealthPLAN Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-500
Closed -$5.5K – 1263
2023
Q1 		$5.5K Buy
+500
New +$7.23K ﹤0.01% 985

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WealthPLAN Partners's ARQT Position: Q2 2023 in Review

WealthPLAN Partners sold out of Arcutis Biotherapeutics (ARQT) in Q2 2023, closing a stake of 500 shares — an estimated $5.5K sold.

WealthPLAN Partners first reported a position in ARQT in Q1 2023 and held it in 1 quarter. The position peaked at $5.5K in Q1 2023. 136 funds tracked by Wall St. Rank hold ARQT as of Q2 2023.

  • WealthPLAN Partners reported no remaining Arcutis Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • WealthPLAN Partners sold 500 Arcutis Biotherapeutics shares in Q2 2023, an estimated $5.5K.
  • WealthPLAN Partners first reported a position in Arcutis Biotherapeutics in Q1 2023 and held it in 1 quarter.
  • WealthPLAN Partners's Arcutis Biotherapeutics position peaked at $5.5K in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2023.

Based on WealthPLAN Partners's 13F filing for Q2 2023, filed 31 Jul 2023.